Request Complimentary Product Samples
COSOPT^® (dorzolamide hydrochloride-timolol maleate ophthalmic solution)

 Patient Product Information

Registered and validated MDs/DOs may print out a form to request complimentary samples of Merck products.

To request complimentary samples, you must sign in. You will then be shown a list of the different complimentary sample formulations for that product that you may request. When you finalize your requests, you will need to print out a Sample Request Form. This form must then be signed, dated, and returned to Merck via fax or mail using the fax number or address specified on the form. You should receive the samples requested via UPS delivery within 14 business days of Merck receiving the completed form.

Viewing files designated with requires a PDF reader

COSOPT is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta blockers (failed to achieve target IOP determined after multiple measurements over time). The IOP-lowering effect of COSOPT bid was slightly less than that seen with the concomitant administration of 0.5% timolol bid and 2.0% dorzolamide tid. COSOPT is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease (see WARNINGS); (4) sinus bradycardia; (5) second- or third-degree atrioventricular block; (6) overt cardiac failure (see WARNINGS); (7) cardiogenic shock; or (8) hypersensitivity to any component of this product. COSOPT contains dorzolamide, a sulfonamide, and timolol maleate, a beta-adrenergic blocking agent; and although administered topically, is absorbed systemically. Therefore, the same types of adverse reactions that are attributable to sulfonamides and/or systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma and, rarely, death in association with cardiac failure, have been reported following systemic or ophthalmic administration of timolol maleate. The concomitant use of two topical beta-adrenergic blocking agents (eg, COSOPT and timolol maleate) is not recommended. Patients should be advised that COSOPT contains benzalkonium chloride, which may be absorbed by soft contact lenses. Contact lenses should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes after administration of COSOPT.